참고문헌
- Aalto ML, Collan Y (1986). Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors. Int J Gynaecol Obstet, 24, 27-34. https://doi.org/10.1016/0020-7292(86)90020-2
- Aggarwal BB, Bhardwaj A, Aggarwal RS, et al (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24, 2783-40.
- Athar M, Back JH, Kopelovich L, Bickers DR, Kim Al (2009). Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys, 486, 95-102. https://doi.org/10.1016/j.abb.2009.01.018
-
Banerjee S, Bueso Ramos C, Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-
${\kappa}B$ , cycloxygenase 2, and matrix metalloprotease 9. Cancer Res, 62, 4945-54. - Becher OJ, Holland EC (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res, 66, 3355-9. https://doi.org/10.1158/0008-5472.CAN-05-3827
- Bishayee A (2009). Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res, 2, 409-18. https://doi.org/10.1158/1940-6207.CAPR-08-0160
- Bishayee A, Dhir N (2009). Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem-Biol Interact, 179, 131-44. https://doi.org/10.1016/j.cbi.2008.11.015
- Bishayee A (2012). Current advances in cancer prevention and treatment by natural products. Curr Pharm Biotechnol, 13, 115-6. https://doi.org/10.2174/138920112798868629
- Bjorklund M, Roos J, Gogvadze V, Shoshan M (2011). Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low dose-dose platinum treatment. Cancer Chemother Pharmacol, 68, 1459-67. https://doi.org/10.1007/s00280-011-1640-x
- Bove K, Lincoln DW, Tsan MF (2001). Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun, 291, 1001-5.
- Brard L, Granai CO, Swamy N (2006). Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol, 100, 116-27. https://doi.org/10.1016/j.ygyno.2005.07.129
- Brewer MA, Johnson K, Follen M, Gershenson D, Bast R, Jr (2003). Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res, 9, 20-30.
-
Cao Z, Fang J, Xia C, Shi X, Jiang BH (2004). trans-3,4,5'- Trihydroxystibene inhibits hypoxia-inducible factor 1
$\alpha$ and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res, 10, 5253-63. https://doi.org/10.1158/1078-0432.CCR-03-0588 - Crowell JA, Korytko PJ, Morrissey Rl, Booth TD, Levine BS (2004). Resveratrol-associated renal toxicity. Toxicol Sci, 82, 614-9. https://doi.org/10.1093/toxsci/kfh263
- Delmas D, Solary E, Latruffe N (2011). Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem, 18, 1100-21. https://doi.org/10.2174/092986711795029708
- Dennis T, Fanous M, Mousa S (2009). Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer, 61, 587-97. https://doi.org/10.1080/01635580902825530
- Feki A, Jefford CE, Berardi P, et al (2005). BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNAdamage response kinase. Oncogene, 24, 3726-37. https://doi.org/10.1038/sj.onc.1208491
- Fremont L (2000). Biological effects of resveratrol. Life Sci, 66, 663-73. https://doi.org/10.1016/S0024-3205(99)00410-5
- Gescher AJ, Steward WP (2003). Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 12, 953-7.
- Gullett NP, Ruhul Amin AR, Bayraktar S, et al. (2010) Cancer prevention with natural compounds. Semin Oncol, 37, 258-81. https://doi.org/10.1053/j.seminoncol.2010.06.014
- Guo L, Peng Y, Yao J, (2010). Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm, 25, 471-7. https://doi.org/10.1089/cbr.2009.0724
- Harikumar KB, kunnumakkara AB, Sethi G, et al. (2010) Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer, 127, 257-68.
- Harper CE, patel BB, Wang J, et al (2007). Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28, 1946-53. https://doi.org/10.1093/carcin/bgm144
- Hebbar V, Shen G, Hu R, et al. (2005) Toxicogenomics of resveratrol in rat liver. Life Sci, 76, 2299-314. https://doi.org/10.1016/j.lfs.2004.10.039
- Hoekstra A, Rodriguez GC (2009). Chemoprevention of ovarian cancer. Cancer Treat Res, 149, 3-34. https://doi.org/10.1007/978-0-387-98094-2_1
- Hsu SM, Raine L, Fanger H (1981). Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between (ABC) and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29, 577-80. https://doi.org/10.1177/29.4.6166661
- Jang M, Cai L, Udeani GO, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-20. https://doi.org/10.1126/science.275.5297.218
- Kueck A, Opipari AW, Griffith KA, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol, 107, 450-7. https://doi.org/10.1016/j.ygyno.2007.07.065
- Kundu JK, Surh YJ (2008). Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett, 269, 243-61. https://doi.org/10.1016/j.canlet.2008.03.057
- Lee MH, Choi BY, Kundu JK, et al (2009). Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res, 69, 7449-58. https://doi.org/10.1158/0008-5472.CAN-09-1266
- Li ZG, Hong T, Shimada Y, et al (2002). Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 23, 1531-6. https://doi.org/10.1093/carcin/23.9.1531
- Lin C, Crawford DR, Lin S, et al. (2011) Inducible COX- 2 dependent apoptosis in human ovarian cancer cells. Carcinogenesis, 32, 19-26. https://doi.org/10.1093/carcin/bgq212
- Marimuthu P, Kaur K, Kandalam U, et al. (2011). Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food, 14, 46-52. https://doi.org/10.1089/jmf.2009.0270
- Medvetz DA, Stakleff KD, Schreiber T, et al. (2007) Ovarian cancer activity of cyclic amine and thiaether metal complexes. J Med Chem, 50, 1703-6. https://doi.org/10.1021/jm060857s
- Mills GB (2002). Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res, 8, 7-10.
- NIH Consensus Development Panel on Ovarian Cancer (1995). Ovarian cancer: screening, treatment and follow-up. J Am Med Assoc, 273, 491-7. https://doi.org/10.1001/jama.1995.03520300065039
- Niles RM, Cook CP, Meadows GG, et al. (2006). Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr, 136, 2542-6.
- Niles RM, Mcfarland M, Weimer MB, et al. (2003) Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett, 190, 157-63. https://doi.org/10.1016/S0304-3835(02)00676-6
- Opipari JR, AW, Tan L, et al (2004). Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res, 64, 696-703. https://doi.org/10.1158/0008-5472.CAN-03-2404
-
Park SY, Jeong KJ, Lee J, et al. (2007) Hypoxia enhances, LPAinduced HIF-
$1{\alpha}$ and VEGF expression: their inhibition by resveratrol. Cancer Lett, 258, 63-9. https://doi.org/10.1016/j.canlet.2007.08.011 - Raj MHG, Abd Elmageed ZY, Zhou J, et al (2008). Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol, 110, 432-8. https://doi.org/10.1016/j.ygyno.2008.05.001
- Rezk YA, Balulad SS, Keller RS, Bennett JA (2006). Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic can cell lines and in rodent heart. Am J Obstet Gynecol, 194, 23-6. https://doi.org/10.1016/j.ajog.2005.11.030
- Rose GS, Toco LM, Granger GA, et al (1996) Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol, 175, 593-9. https://doi.org/10.1053/ob.1996.v175.a73595
- Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25. https://doi.org/10.1016/j.bpobgyn.2005.10.007
- Schneider Y, Duranton B, Gosse F, et al (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defenserelated gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer, 39, 102-7. https://doi.org/10.1207/S15327914nc391_14
- Schumacher JJ, Dings RPM, Costin J, et al (2007). Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res, 67, 3683-90. https://doi.org/10.1158/0008-5472.CAN-06-3608
- Sengottuvelan M, Viswanathan P, Nalini N (2006). Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 27, 1038-46. https://doi.org/10.1093/carcin/bgi286
- Shukla Y, Singh R (2011). Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci, 1215, 1-8. https://doi.org/10.1111/j.1749-6632.2010.05870.x
- Siegel R, Naishadham, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
- Sloan Stakleff KD, Rouse AG, Ryan AP, Haller NA, Von Gruenigen VE (2005). A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. Int J Gynecol Cancer, 15, 246-54. https://doi.org/10.1111/j.1525-1438.2005.15211.x
- Sloan Stakleff KD, Von Gruenigen VE (2003). Rodent models for ovarian cancer research. Int J Gynecol Cancer, 13, 405-12. https://doi.org/10.1046/j.1525-1438.2003.13317.x
- Smith ER, Daly MB, Xu XX (2004). A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidem Biomarkers Prev, 13, 144-5. https://doi.org/10.1158/1055-9965.EPI-461-2
- Stan SD, Kar S, Stoner GD, Singh SV (2008). Bioactive food components and cancer risk reduction. J Cell Biochem, 104, 339-56. https://doi.org/10.1002/jcb.21623
- Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med, 216, 201-10. https://doi.org/10.3181/00379727-216-44170
- Subramanian L, Youssef S, Bhattacharya S, et al. (2010) Resveratrol: challenges in translation to the clinic - a critical discussion. Clin Cancer Res, 16, 5942-8. https://doi.org/10.1158/1078-0432.CCR-10-1486
- Teicher BA (2006). Tumor models for efficacy determination. Mol Cancer Ther, 5, 2435-43. https://doi.org/10.1158/1535-7163.MCT-06-0391
- Tessitore L, Davit A, Sarotto I, Caderni G (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis, 21, 1619-22. https://doi.org/10.1093/carcin/21.8.1619
- Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sciafani RA (2005). Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 26, 1978-87. https://doi.org/10.1093/carcin/bgi165
- Visintin I, Feng A, Longton G, et al (2008). Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14, 1065-72. https://doi.org/10.1158/1078-0432.CCR-07-1569
- Weng CJ, Yen GC (2012). Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev, 38, 76-87. https://doi.org/10.1016/j.ctrv.2011.03.001
- Yang SH, Kim JS, Oh TJ, et al (2003) Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol, 22, 741-50.
- Zhou H-B, Chen J-J, Wang W-X, Cai J-T, Du Q (2005). Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol, 11, 280-4. https://doi.org/10.3748/wjg.v11.i2.280
피인용 문헌
- Anticarcinogenic, Cardioprotective, and Other Health Benefits of Tomato Compounds Lycopene, α-Tomatine, and Tomatidine in Pure Form and in Fresh and Processed Tomatoes vol.61, pp.40, 2013, https://doi.org/10.1021/jf402654e
- Targeting Cancer with Nano-Bullets: Curcumin, EGCG, Resveratrol and Quercetin on Flying Carpets vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3865
- Molecular Approaches Toward Targeted Cancer Prevention with Some Food Plants and Their Products: Inflammatory and Other Signal Pathways vol.66, pp.2, 2014, https://doi.org/10.1080/01635581.2014.864420
- Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3759
- Antiangiogenic Activity of Mononuclear Copper(II) Polypyridyl Complexes for the Treatment of Cancers vol.58, pp.13, 2015, https://doi.org/10.1021/acs.jmedchem.5b00651
- Gene expression profiling of DMU-212-induced apoptosis and anti-angiogenesis in vascular endothelial cells vol.54, pp.4, 2016, https://doi.org/10.3109/13880209.2015.1071414
- Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems vol.2017, pp.1687-8469, 2017, https://doi.org/10.1155/2017/7351976
- The Role of Resveratrol in Cancer Therapy vol.18, pp.12, 2017, https://doi.org/10.3390/ijms18122589